Covid-19 treatment: Sun Pharma gets DCGI approval for Nafamostat clinical trial in patients
Team Udayavani, May 30, 2020, 4:04 PM IST
The Drug Controller General of India has approved Sun Pharmaceutical Industries Ltd’s clinical trial with nafamostat mesilate in covid-19 patients
Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of disseminated intravascular coagulation (DIC)
Scientists from the University of Tokyo in Japan and Leibniz Institute for Primate Research in Germany recently demonstrated that Nafamostat at very low concentrations suppresses a protein that the Covid-19 virus uses to enter human lung cells.
Dilip Shanghvi, Managing Director, Sun Pharma said, “Sun Pharma is constantly evaluating potential targets that can be explored for treating Covid-19 patients. Nafamostat has shown promising data against SARS-CoV-2 virus in in-vitro studies conducted by three independent groups of scientists in Europe, Japan and South Korea. We believe it holds promise in the treatment of Covid-19 patients
Sun Pharma is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Exposure to outdoor artificial light at night may increase risk of stroke, study finds
Group of oncologists launch free-of-cost second opinion helpline number for cancer patients
Dogs understand more than they let on, create mental images of known words: Study
Caution advised as diarrhoea cases rise with onset of summer
Bharat Biotech begins clinical trials of TB vaccine on adults in India
MUST WATCH
Latest Additions
Height of hypocrisy: Cong hits back at PM over his jibe after lawyers’ letter to CJI
Cong slams Irani for ‘silence’ on women’s issues, asks her to put forward 10-year ‘report card’
One vote can change country’s fate: UP CM Adityanath
Bengaluru: Two arrested for illegally seizing auto over alleged loan default
To browbeat, bully others is vintage Congress culture: PM Modi on lawyers’ letter to CJI